🎥 Episode 5 of Meeting the People Behind the Science is here! In the fifth and final episode, meet Élodie, Hélia, and Luc, three talented scientists from our Lyon lab. This team's passion, perspective, and collaboration reflect KCAS Bio's core values and shows in the work that they do. This episode shows the diverse people and ideas that make our teams thrive. We’re proud to highlight our culture and teamwork across the globe. 🌎 #KCASBio #BehindTheScience #MeetTheTeam
KCAS Bio
Biotechnology Research
Olathe, Kansas 16,429 followers
A contract research organization (CRO) advancing the latest in drug development with leading sponsors, worldwide.
About us
KCAS Bio is a top-tier contract research organization (CRO) that has 45 years of experience with both large pharma and biotech sponsors, providing comprehensive bioanalytical drug development services from early discovery through registration. We have supported more than 315 FDA approved drugs on the market, developed 6,200+ proprietary and non-proprietary assays to date, and undergone 18 FDA audits with no major findings. Our presence in multiple locations throughout the US and Europe - and with a strategic alliance in Australia - allows us to serve sponsors globally with bioanalytical, biomarker, immunogenicity, cellular and molecular assay services along with clinical kitting and sample management. With the expertise, capacity and flexibility sponsors require, we can fulfill our purpose, which is to help accelerate the discovery and development of life-changing drugs smoothly, safely and sustainably.
- Website
-
http://www.kcasbio.com
External link for KCAS Bio
- Industry
- Biotechnology Research
- Company size
- 201-500 employees
- Headquarters
- Olathe, Kansas
- Type
- Privately Held
- Founded
- 1979
- Specialties
- Immunogenicity (ADA), Flow Cytometry, Vaccines, Method Dev + Transfer, Clinical PK/PD Kits, LC-MS/MS, GLP, GCP, non-GLP, ECL - MSD, ELISA, Biopharma LC-MS/MS, Receptor Occupancy, Luminex, Biomarkers, PD Biomarkers, PK / TK, and Hybrid LC-MS/MS
Locations
-
Primary
Get directions
10830 S Clay Blair Blvd
Olathe, Kansas 66061, US
-
Get directions
727 Norristown Rd
Building 4, Suite 200
Lower Gwynedd, Pennsylvania 19002, US
-
Get directions
60 f, Avenue Rockefeller
BIOSERRA 2 Building, 3rd Floor
Lyon, Auvergne-Rhône-Alpes 69008, FR
Employees at KCAS Bio
Updates
-
The University of Kansas Medical Center is advancing a new CAR T-cell therapy trial that underscores the power of collaboration in moving life-changing science forward. At KCAS Bio, we’re proud to provide the bioanalytical support that helps make breakthroughs like this possible, turning complex science into measurable impact for patients.
A treatment known as CAR T-cell therapy has been a game changer for many people with blood cancers such as lymphoma and leukemia. But not everyone responds to CAR T-cell therapy or stays in remission. For some, the cancer develops resistance to the drug. Researchers at The University of Kansas Cancer Center have launched a clinical trial for a new form of CAR T-cell therapy dubbed "Triple Threat," which triples the drug's number of molecular targets to circumvent the cancer's resistance to treatment. Learn more about the investigator-initiated trial:
-
Mouhssin OUFIR, PhD, and Charisse Fernandez will be traveling to the International Reid Bioanalytical Forum, held in Cambourne, UK, September 8–11, 2025. Read more: https://lnkd.in/gTjnR2kv A cornerstone in the bioanalysis calendar, this forum convenes scientists, industry leaders, instrument makers, CROs, and academics to explore the latest in bioanalytical practices, challenges, and innovations. If you'll be attending too, please reach out to Mouhssin OUFIR, PhD, or Charisse Fernandez to connect at the forum. We’d love to discuss how KCAS Bio can partner with you on your next project or scientific study. Learn more about KCAS Bio here: https://kcasbio.com/ See you in Cambourne!
-
-
A study’s success hinges on more than the assays themselves. It begins with the sample matrix you choose. This reference guide explores the scientific and practical considerations that shape matrix selection, including antigen stability, anticoagulant effects, shipping logistics, and fixation strategies. With these factors in mind, sponsors and planners can align sample choice with both real-world study constraints and long-term scientific goals. Making the right decision at this stage helps ensure fewer surprises and more meaningful, actionable results. Click here to read the full guide authored by Christy Bucks, Ph.D., who shares her expertise to support better decision-making in flow cytometry study design: https://lnkd.in/gHMB9F6N #Bioanalysis #FlowCytometry #SampleMatrix #DrugDevelopmentTools #TranslationalMedicine #ClinicalStudyDesign #ScientificExcellence #PharmaInnovation #BiomarkerTesting #DataQuality
-
🎥 Watch Episode 4 of Meeting the People Behind the Science! In this episode, meet Sample Control Agent Team, Kamden Miller, and learn more about the people within our Lab Support Services - Test Materials Management team. Kamden's passion for science and people shows in the work he does. His perspective highlights the importance of precision, teamwork, and drive in keeping our science moving forward. Watch the full episode to meet another shining personality that represents KCAS Bio. #KCASBio #BehindTheScience #MeetTheTeam
-
Our scientists don’t just drive innovation in the lab; they’re also out in the scientific community sharing their expertise. We’re proud to share that Dawn Dufield, Ph.D, Scientific Officer, Mass Spectrometry at KCAS Bio, will be a featured speaker at an upcoming SCIEX event in San Diego. Dawn Dufield, Ph.D will be discussing LC-MS/MS bioanalytical strategies for various therapeutic drugs and their conjugates [ADCs, Oligos, siRNA, ASOs and AOCs/ACRs] by QQQ and HRMS. Learn more about Dawn by checking out her profile in the Mass Spec Bioanalysis Community on Linked In: https://lnkd.in/dEDAhtxF #KCASBio #SCIEX #DrugDevelopment #Bioanalysis #ScientificExcellence
Another week, another member from the BioA community: Have you met Dawn Dufield, Ph.D – Scientific Officer, Mass Spectrometry at KCAS Bio❓ 𝗪𝗵𝗮𝘁'𝘀 𝘆𝗼𝘂𝗿 𝗯𝗮𝗰𝗸𝗴𝗿𝗼𝘂𝗻𝗱 𝗗𝗮𝘄𝗻? I have 30 years of professional experience in the field. I’m based in Kansas City, KS (United States). 🔧 𝗧𝗲𝗹𝗹 𝘂𝘀 𝗮𝗯𝗼𝘂𝘁 𝘆𝗼𝘂𝗿 𝗳𝗶𝗿𝘀𝘁/𝗳𝗮𝘃𝗼𝗿𝗶𝘁𝗲 𝗠𝗦 𝗶𝗻𝘀𝘁𝗿𝘂𝗺𝗲𝗻𝘁. My first instrument was the SCIEX API III. I think we all remember that you had to check with everyone before you hit the recycle button, as that would take the instrument down for a day. Ahh, the not-so-good old days! 🧫 𝗦𝗺𝗮𝗹𝗹 𝗼𝗿 𝗹𝗮𝗿𝗴𝗲 𝗺𝗼𝗹𝗲𝗰𝘂𝗹𝗲𝘀? I love working with protein and surrogate peptide quantitation using hybrid LC-MS/MS workflows, especially post-immunoaffinity enrichment. I also love (and hate) quantitating what others think isn’t possible. 💀 𝗕𝗶𝗼𝗔 𝗰𝗵𝗮𝗹𝗹𝗲𝗻𝗴𝗲𝘀: 𝗧𝗲𝗹𝗹 𝘂𝘀 𝘄𝗵𝗮𝘁 𝘆𝗼𝘂 𝘀𝘁𝗶𝗹𝗹 𝗵𝗮𝘃𝗲 𝗻𝗶𝗴𝗵𝘁𝗺𝗮𝗿𝗲𝘀 𝗮𝗯𝗼𝘂𝘁... I still have nightmares about compounds that are either incredibly sticky and cause carryover, or ones that won’t stick at all and have zero chromatographic retention. 👉 𝗪𝗵𝗮𝘁 𝗮𝗯𝗼𝘂𝘁 𝘆𝗼𝘂? If you want to be part of this post series, contact Kirsten Craven or me to be featured. #Bioanalysis #MassSpectrometry #Biopharma #Pharma #SCIEX #MeetTheBioACommunity #KCASBio
-
-
Check out the latest episode of "The Conversational Flow" #podcast from KCAS Bio! In Episode #23 of #TheConversationalFlow podcast, Adam C. and Brian Wile, PhD dive into an important question: When can #FlowCytometry be applied to non-blood matrices—and what must be considered? From #SputumAnalysis in #LungCancerResearch to other nontraditional sample types, they unpack: • Pre-analytical challenges: collection, bias, and logistics • Designing panels and choosing the right reagents • Gating strategies and quality control for reliable results • How flow data compares with spatial insights from solid tissues • What types of decisions flow cytometry can realistically support Whether you’re developing assays, running #ClinicalTrials, or just curious about how far flow cytometry can go, this episode offers a candid look at the possibilities and limitations. 🎧 Listen to the newest episode now: https://lnkd.in/gybpWGYv #FlowCytometry #ClinicalTrials #Bioanalysis #Diagnostics #KCASBio
-
Monitoring anti-drug antibodies (ADAs) isn’t a checkbox. It’s foundational to understanding how a therapeutic interacts with the immune system. Our latest blog by KCAS Bio Scientific Advisor, Lindsay Rutherford, Ph.D., walks through the importance of ADA assay development, from early surrogate antibody generation to clinical validation, and why getting ahead of immunogenicity can inform safety, efficacy, and IND readiness. For sponsors, investing in immunogenicity insight early means stronger confidence in program advancement before unexpected immune surprises emerge. Click here to explore the science-driven approach to ADA assays: https://lnkd.in/gavvzEkd #Immunogenicity #AntidrugAntibodies #ADAAssays #DrugDevelopment #ClinicalSafety #Biotherapeutics #Bioanalysis #TranslationalScience
-
Episode 3 is here! 🎥 In this episode of Meeting the People Behind the Science, meet Nathan Gulbis, a Senior Scientist- Principal Investigator in Biopharma Sciences at KCAS Bio. Nathan shares what first drew him to the biopharma field, a memorable project that left a lasting impact, and the advice to young scientists. His perspective offers both inspiration for future scientists and a candid look at what it’s like to be part of our team. Check out the full episode to hear his story and see why his passion for science helps drive the work we do every day. #KCASBio #BehindTheScience #MeetTheTeam
-
Cytotoxicity assays are more than a checkbox, they’re a window into how a therapy behaves in the real world. And in our experience, flow cytometry makes that window wider, clearer, and more actionable. By delivering high-content, single-cell insights, flow cytometry can distinguish immune activation from true cytotoxicity, uncovering subtle safety signals that traditional averaged readouts might miss. For sponsors, that means making informed decisions earlier, before costly setbacks. Explore how this approach could change the way you view cytotoxicity results: https://lnkd.in/gqAgEB_E #FlowCytometry #DrugDevelopment #SafetyAssessment #Cytotoxicity #Bioanalysis #PreclinicalTesting #BiotechInnovation #ScientificExcellence